These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 17012539)

  • 1. The disposition and metabolism of naveglitazar, a peroxisome proliferator-activated receptor alpha-gamma dual, gamma-dominant agonist in mice, rats, and monkeys.
    Yi P; Hadden CE; Annes WF; Jackson DA; Peterson BC; Gillespie TA; Johnson JT
    Drug Metab Dispos; 2007 Jan; 35(1):51-61. PubMed ID: 17012539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling.
    Zhang D; Wang L; Raghavan N; Zhang H; Li W; Cheng PT; Yao M; Zhang L; Zhu M; Bonacorsi S; Yeola S; Mitroka J; Hariharan N; Hosagrahara V; Chandrasena G; Shyu WC; Humphreys WG
    Drug Metab Dispos; 2007 Jan; 35(1):150-67. PubMed ID: 17062777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics, metabolism, and disposition of rivoglitazone, a novel peroxisome proliferator-activated receptor γ agonist, in rats and monkeys.
    Uchiyama M; Iwabuchi H; Tsuruta F; Abe K; Takahashi M; Koda H; Oguchi M; Okazaki O; Izumi T
    Drug Metab Dispos; 2011 Apr; 39(4):653-66. PubMed ID: 21177486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical pharmacokinetics and interspecies scaling of ragaglitazar, a novel biliary excreted PPAR dual activator.
    Pavankuamr VV; Vinu CA; Mullangi R; Srinivas NR
    Eur J Drug Metab Pharmacokinet; 2007; 32(1):29-37. PubMed ID: 17479541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allometric prediction of the human pharmacokinetic parameters for naveglitazar.
    Ahlawat P; Srinivas NR
    Eur J Drug Metab Pharmacokinet; 2008; 33(3):187-90. PubMed ID: 19007045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereoselectivity in pharmacokinetics of rivoglitazone, a novel peroxisome proliferator-activated receptor γ agonist, in rats and monkeys: model-based pharmacokinetic analysis and in vitro-in vivo extrapolation approach.
    Izumi T; Tsuruta F; Ishizuka T; Nakamura K; Kothuma M; Takahashi M
    J Pharm Sci; 2013 Sep; 102(9):3174-88. PubMed ID: 23686684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics, disposition and lipid-modulating activity of 5-{2-[4-(3,4-difluorophenoxy)-phenyl]-ethylsulfamoyl}-2-methyl-benzoic acid, a potent and subtype-selective peroxisome proliferator-activated receptor alpha agonist in preclinical species and human.
    Frederick KS; Maurer TS; Kalgutkar AS; Royer LJ; Francone OL; Winter SM; Terra SG; Chen D; Gao X
    Xenobiotica; 2009 Oct; 39(10):766-81. PubMed ID: 19622022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoplastic and non-neoplastic changes in F-344 rats treated with Naveglitazar, a gamma-dominant PPAR alpha/gamma agonist.
    Long GG; Reynolds VL; Dochterman LW; Ryan TE
    Toxicol Pathol; 2009 Oct; 37(6):741-53. PubMed ID: 19700659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics, disposition, and metabolism of bicifadine in the mouse, rat, and monkey.
    Musick TJ; Gohdes M; Duffy A; Erickson DA; Krieter PA
    Drug Metab Dispos; 2008 Feb; 36(2):241-51. PubMed ID: 17991767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and metabolism of tesaglitazar, a novel dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist, after a single oral and intravenous dose in humans.
    Ericsson H; Hamrén B; Bergstrand S; Elebring M; Fryklund L; Heijer M; Ohman KP
    Drug Metab Dispos; 2004 Sep; 32(9):923-9. PubMed ID: 15319332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Species differences in the biotransformation of an alpha 4 beta 2 nicotinic acetylcholine receptor partial agonist: the effects of distinct glucuronide metabolites on overall compound disposition.
    Shaffer CL; Gunduz M; Ryder TF; O'Connell TN
    Drug Metab Dispos; 2010 Feb; 38(2):292-301. PubMed ID: 19910512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma stability-dependent circulation of acyl glucuronide metabolites in humans: how circulating metabolite profiles of muraglitazar and peliglitazar can lead to misleading risk assessment.
    Zhang D; Raghavan N; Wang L; Xue Y; Obermeier M; Chen S; Tao S; Zhang H; Cheng PT; Li W; Ramanathan R; Yang Z; Humphreys WG
    Drug Metab Dispos; 2011 Jan; 39(1):123-31. PubMed ID: 20876787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic fate of sipoglitazar, a novel oral PPAR agonist with activities for PPAR-γ, -α and -δ, in rats and monkeys and comparison with humans in vitro.
    Nishihara M; Sudo M; Kamiguchi H; Kawaguchi N; Maeshiba Y; Kiyota Y; Takahashi J; Tagawa Y; Kondo T; Asahi S
    Drug Metab Pharmacokinet; 2012; 27(2):223-31. PubMed ID: 22123126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urothelial carcinogenesis in the urinary bladder of rats treated with naveglitazar, a gamma-dominant PPAR alpha/gamma agonist: lack of evidence for urolithiasis as an inciting event.
    Long GG; Reynolds VL; Lopez-Martinez A; Ryan TE; White SL; Eldridge SR
    Toxicol Pathol; 2008 Feb; 36(2):218-31. PubMed ID: 18474944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disposition of a new nonsteroidal anti-inflammatory agent, S-2-[4-(3-methyl-2-thienyl)phenyl]propionic acid, in rats, dogs and monkeys.
    Konishi T; Okada S; Nishikawa H; Esumi Y; Kitamura S; Tatsumi K
    Arzneimittelforschung; 1998 Mar; 48(3):266-74. PubMed ID: 9553685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolism, distribution, and excretion of a next generation selective estrogen receptor modulator, lasofoxifene, in rats and monkeys.
    Prakash C; Johnson KA; Schroeder CM; Potchoiba MJ
    Drug Metab Dispos; 2008 Sep; 36(9):1753-69. PubMed ID: 18515329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biotransformation of carbon-14-labeled muraglitazar in male mice: interspecies difference in metabolic pathways leading to unique metabolites.
    Li W; Zhang D; Wang L; Zhang H; Cheng PT; Zhang D; Everett DW; Humphreys WG
    Drug Metab Dispos; 2006 May; 34(5):807-20. PubMed ID: 16467134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cevoglitazar, a novel peroxisome proliferator-activated receptor-alpha/gamma dual agonist, potently reduces food intake and body weight in obese mice and cynomolgus monkeys.
    Chen H; Dardik B; Qiu L; Ren X; Caplan SL; Burkey B; Boettcher BR; Gromada J
    Endocrinology; 2010 Jul; 151(7):3115-24. PubMed ID: 20484464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of muraglitazar (BMS-298585), a dual peroxisome proliferator-activated receptors (PPAR) alpha and gamma activator, in mice, rats, dogs, and monkeys.
    Hosagrahara VP; Chandrasena G; Chang SY; Koplowitz B; Hariharan N; Cheng PT; Humphreys WG
    Xenobiotica; 2006 Dec; 36(12):1227-38. PubMed ID: 17162469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical characterization of 2-[3-[3-[(5-ethyl-4'-fluoro-2-hydroxy[1,1'-biphenyl]-4-yl)oxy]propoxy]-2-propylphenoxy]benzoic acid metabolism: in vitro species comparison and in vivo disposition in rats.
    Perkins EJ; Cramer JW; Farid NA; Gadberry MG; Jackson DA; Mattiuz EL; O'Bannon DD; Weiss HJ; Wheeler WJ; Wood PG; Cassidy KC
    Drug Metab Dispos; 2003 Nov; 31(11):1382-90. PubMed ID: 14570771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.